GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » ROIC %

Scancell Holdings (LSE:SCLP) ROIC % : -141.06% (As of Oct. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Scancell Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Oct. 2023 was -141.06%.

As of today (2024-04-29), Scancell Holdings's WACC % is 11.48%. Scancell Holdings's ROIC % is -153.06% (calculated using TTM income statement data). Scancell Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Scancell Holdings ROIC % Historical Data

The historical data trend for Scancell Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings ROIC % Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.51 -110.40 -152.82 -131.40 -112.23

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -200.93 -166.38 -31.77 -160.24 -141.06

Competitive Comparison of Scancell Holdings's ROIC %

For the Biotechnology subindustry, Scancell Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's ROIC % falls into.



Scancell Holdings ROIC % Calculation

Scancell Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Apr. 2023 is calculated as:

ROIC % (A: Apr. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Apr. 2022 ) + Invested Capital (A: Apr. 2023 ))/ count )
=-11.92 * ( 1 - 16.55% )/( (8.885 + 8.842)/ 2 )
=-9.94724/8.8635
=-112.23 %

where

Scancell Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Oct. 2023 is calculated as:

ROIC % (Q: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2023 ) + Invested Capital (Q: Oct. 2023 ))/ count )
=-16.24 * ( 1 - 28.99% )/( (8.842 + 7.509)/ 2 )
=-11.532024/8.1755
=-141.06 %

where

Note: The Operating Income data used here is two times the semi-annual (Oct. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (LSE:SCLP) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Scancell Holdings's WACC % is 11.48%. Scancell Holdings's ROIC % is -153.06% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Scancell Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (LSE:SCLP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines